Retatrutide for NASH: Off-Label Use, Evidence, and Monitoring Requirements

What Is Retatrutide and Why Is It Being Discussed for NASH?

Retatrutide is an investigational once-weekly subcutaneous peptide that simultaneously activates three receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. No other approved drug targets all three pathways at once. The FDA has not approved retatrutide for any indication as of July 2025; it remains in late-stage clinical development for obesity and type 2 diabetes.

NASH, or nonalcoholic steatohepatitis, is now renamed metabolic dysfunction-associated steatohepatitis (MASH) in the updated nomenclature endorsed by major liver societies. It affects an estimated 1.5 to 6.5% of the global adult population and is the fastest-growing indication for liver transplantation in the United States, according to data from the National Institute of Diabetes and Digestive and Kidney Diseases.

The rationale for using retatrutide off-label in MASH rests on three biological pathways.

GLP-1 Receptor Activation Reduces Hepatic Steatosis

GLP-1 receptor agonists already have a documented liver signal. Semaglutide 2.4 mg produced NASH resolution without worsening fibrosis in 59% of participants in the NASH phase 2 trial (N=320, 72 weeks) published in the New England Journal of Medicine [1]. Retatrutide carries this same mechanism, plus two additional ones.

Glucagon Receptor Activation Drives Hepatic Fat Oxidation

Glucagon stimulates fatty acid oxidation in the liver and reduces hepatic lipogenesis. This is a mechanism absent from approved GLP-1 monotherapy drugs. Preclinical models of MASH show that glucagon receptor co-agonism reduces liver triglyceride content independently of body-weight loss [2].

GIP Receptor Activation Improves Adipose Tissue Metabolism

GIP agonism modulates adipose tissue lipid storage and free-fatty-acid flux to the liver. Excess free fatty acid delivery is one of the central drivers of hepatic steatosis. By acting at all three sites, retatrutide may produce a synergistic effect on liver fat that exceeds what any single-pathway drug achieves. The word "synergistic" here describes a mechanistic hypothesis, not a proven clinical outcome.

What Does the Phase 2 Evidence Actually Show?

The Phase 2 Obesity Trial (NCT04881760)

The key phase 2 retatrutide trial enrolled 338 adults with obesity (BMI 30 or greater) or overweight (BMI 27 or greater) with at least one weight-related comorbidity and randomized them to one of five retatrutide doses or placebo for 48 weeks [3]. Published in the New England Journal of Medicine in 2023, the trial reported:

• The 12 mg retatrutide group lost a mean of 24.2% of body weight at 48 weeks vs. 2.1% with placebo (P<0.001).
• The 8 mg group lost 22.8%.
• All active-dose groups showed statistically significant reductions in waist circumference, triglycerides, and fasting glucose compared to placebo.

Liver-specific endpoints were not the primary outcome, but exploratory analyses of alanine aminotransferase (ALT) and liver fat by MRI-PDFF in a subset of participants with elevated baseline liver fat showed reductions at 24 weeks. These substudy data have not been published as a standalone peer-reviewed manuscript as of this writing. Clinicians should treat them as hypothesis-generating, not confirmatory.

GRADE Evidence Rating for MASH

Applying the GRADE framework to the current retatrutide-MASH evidence yields a rating of Low. The reasons:

1. No randomized controlled trial has been designed or powered for MASH histological outcomes with retatrutide.
2. The available liver data are from post-hoc or exploratory analyses of a weight-loss trial.
3. No study has reported fibrosis stage improvement as an endpoint with retatrutide.

The American Association for the Study of Liver Diseases (AASLD) 2023 Practice Guidance states: "Pharmacotherapy for MASH should be reserved for patients with at-risk MASH (significant fibrosis, stages F2-F4) where the benefit-risk ratio is most favorable." [4] This guidance was written before FDA approval of resmetirom, but the principle remains applicable when evaluating any off-label agent.

How Retatrutide Compares to the Only FDA-Approved MASH Drug

Resmetirom (Rezdiffra), a thyroid hormone receptor beta agonist, received FDA approval in March 2024 specifically for adults with MASH and moderate to advanced fibrosis (F2-F3). The MAESTRO-NASH trial (N=966) showed NASH resolution without worsening fibrosis in 25.9% of participants on 80 mg vs. 14.2% placebo, and fibrosis improvement of at least one stage in 24.2% vs. 14.2% placebo [5], as published in the New England Journal of Medicine. Retatrutide has no comparable histological endpoint data.

Who Might a Clinician Consider for Off-Label Retatrutide in MASH?

The following framework is intended to guide the clinical conversation, not to substitute for individualized physician judgment. Off-label prescribing of retatrutide for MASH sits outside any current guideline recommendation.

Potential candidates (all criteria must apply):

• Documented MASH on liver biopsy or high-probability MASH by validated non-invasive testing (e.g., FIB-4 <2.67 with elevated liver fat on MRI-PDFF plus ALT >2x ULN)
• Concurrent obesity (BMI 30 or greater) or overweight with metabolic comorbidity, making retatrutide's primary weight-loss indication clinically relevant
• Failure or intolerance of lifestyle modification for at least 6 months with inadequate weight loss (less than 5% of body weight)
• Resmetirom is either contraindicated, not tolerated, or not covered by insurance after appeal
• No active pancreatitis, personal or family history of medullary thyroid carcinoma, or multiple endocrine neoplasia type 2
• Documented informed consent that explicitly acknowledges off-label status, investigational evidence base, and unknown long-term liver safety profile

Relative contraindications:

• Decompensated cirrhosis (Child-Pugh B or C)
• Active hepatitis B or C without viral suppression
• Severe gastroparesis
• Pregnancy or anticipated pregnancy

Off-Label Prescribing: Legal and Ethical Obligations

Off-label prescribing is legal in the United States. The FDA regulates drug approval, not physician prescribing practice. The FDA's guidance on off-label use notes that approved drugs may be used for unapproved indications when a licensed physician determines it is medically appropriate [6].

Several obligations apply:

1. Informed consent must be documented. The patient must understand that retatrutide is investigational for MASH, that no phase 3 MASH trial data exist, and that approved alternatives (resmetirom, lifestyle modification) should be considered first.
2. Insurance will almost certainly not cover this indication. The prescribing clinician should counsel the patient on out-of-pocket cost, which may exceed $1,200 per month for compounded or imported formulations.
3. Compounded retatrutide is not equivalent to the investigational drug used in trials. No commercial retatrutide formulation is FDA-approved as of July 2025. Any dispensed product comes from compounding pharmacies, which are not FDA-approved manufacturers for this molecule.

Monitoring Requirements for Off-Label Retatrutide in MASH

Because both retatrutide and MASH carry distinct safety signals that can interact, a structured monitoring schedule is not optional. The framework below reflects the combined requirements of GLP-1/glucagon class safety surveillance and MASH disease monitoring.

Baseline Workup (Before First Dose)

| Test | Rationale | |---|---| | LFTs (AST, ALT, GGT, ALP, bilirubin) | Establish hepatic baseline; identify decompensation | | Albumin, INR, platelet count | Assess synthetic function and portal hypertension | | FIB-4 score | Non-invasive fibrosis staging | | MRI-PDFF (preferred) or liver biopsy | Quantify liver fat and fibrosis stage | | Fasting lipid panel | Triglycerides may worsen transiently with glucagon agonism | | Fasting glucose, HbA1c | Assess glycemic status | | Comprehensive metabolic panel (renal function) | GLP-1 agents can cause acute kidney injury via volume depletion | | Serum lipase and amylase | Pancreatitis baseline | | Calcitonin (if clinically indicated) | MTC risk; consider in patients with thyroid nodules | | Pregnancy test (women of childbearing age) | Contraindication |

Monitoring at Weeks 4, 8, and 12 (Titration Phase)

The most frequent adverse events in the phase 2 trial were nausea (45%), vomiting (25%), diarrhea (21%), and constipation (15%) at the 12 mg dose [3]. During titration:

• Check renal function and electrolytes if GI adverse events are significant (dehydration risk).
• Repeat serum lipase if abdominal pain develops. Discontinue if lipase exceeds 3x the upper limit of normal with symptoms.
• Assess body weight and record percentage change from baseline.
• Review medication list for drugs with narrow therapeutic windows; GI motility changes can alter absorption.

Monitoring at Months 3, 6, and 12

• Repeat full LFT panel. ALT normalization or reduction of 30% or more from baseline is a reasonable efficacy signal, though it does not confirm histological improvement.
• Repeat FIB-4 at 6 and 12 months. An FIB-4 decrease of 0.3 or more has been proposed as a clinically meaningful change in some observational cohorts, though this has not been validated as a surrogate endpoint in MASH trials.
• Consider repeat MRI-PDFF at 6 months if baseline liver fat was 10% or greater by MRI-PDFF. A relative reduction of 30% or more in liver fat percentage is the threshold used as a surrogate endpoint in several MASH trials, including the semaglutide phase 2 study [1].
• Repeat HbA1c and fasting glucose.
• Assess cardiovascular risk factors.

When to Stop Retatrutide

Discontinue and refer to hepatology if any of the following occur:

• ALT rises to more than 3x baseline on two consecutive measurements taken 2 weeks apart without another explanation.
• New-onset jaundice or bilirubin elevation above 2x ULN.
• Clinical signs of decompensation: ascites, encephalopathy, variceal bleeding.
• Lipase elevation above 3x ULN with abdominal pain (acute pancreatitis protocol).
• Patient develops medullary thyroid carcinoma or MEN2 diagnosis.

Gastrointestinal Adverse Events: What Patients Should Expect

The GI adverse event profile of retatrutide is consistent with other GLP-1-based drugs but appears more pronounced at higher doses due to the added glucagon component. In the 12 mg cohort of NCT04881760, 8.3% of participants discontinued due to adverse events, compared to 0% in the placebo group [3].

Nausea typically peaks during the titration phase (weeks 1 through 12) and attenuates at stable dosing. Strategies used in the trial included:

• Slow dose titration (starting at 0.5 mg and escalating over 24 weeks to 12 mg)
• Small, low-fat meals
• Avoidance of eating to the point of fullness
• Temporary dose reduction if symptoms are severe

Patients with MASH who already have some degree of gastroparesis from autonomic dysfunction (more common in concurrent type 2 diabetes) may tolerate titration poorly. A slower-than-protocol titration schedule, discussed with the prescribing clinician, may reduce dropout.

What the Current Guidelines Say About MASH Pharmacotherapy

AASLD 2023 Practice Guidance

The AASLD 2023 guidance, the most current major liver society document, recommends that pharmacotherapy for MASH be directed at patients with at-risk disease (F2 fibrosis or greater) [4]. It does not mention retatrutide, which is expected given the drug's investigational status at the time of publication.

The guidance states that GLP-1 receptor agonists "may be considered in patients with MASH and concurrent obesity or type 2 diabetes," citing the semaglutide phase 2 data as the primary supporting evidence. This creates a reasonable, if imperfect, analogy for retatrutide, which encompasses GLP-1 agonism plus additional mechanisms.

Endocrine Society and AACE Position

The American Association of Clinical Endocrinology (AACE) 2022 Obesity Clinical Practice Guidelines recommend GLP-1 receptor agonist-based therapy as preferred pharmacotherapy for obesity with metabolic comorbidities, including fatty liver disease [7]. This provides some framework for treating the underlying obesity that drives MASH, even if the liver endpoint itself is off-label.

What No Guideline Yet Covers

No published guideline from AASLD, AACE, the Endocrine Society, or any other major body has addressed retatrutide specifically for MASH. Clinicians operating in this space are working ahead of the guidelines and bear full responsibility for individualized risk-benefit documentation.

Ongoing and Anticipated Research

A dedicated phase 2b/3 MASH trial with retatrutide is anticipated. Eli Lilly has registered interest in a MASH program based on the mechanistic rationale and the liver fat data from NCT04881760. As of July 2025, no phase 3 MASH-specific trial with retatrutide has published a registration number on ClinicalTrials.gov.

The competing field is moving quickly. Tirzepatide (Mounjaro/Zepbound), another dual GIP/GLP-1 agonist by Eli Lilly, is in the SURMOUNT-NASH trial. Data from that trial will likely inform expectations for retatrutide given the mechanistic overlap, with the main difference being retatrutide's additional glucagon receptor activity.

Researchers at the National Institute of Diabetes and Digestive and Kidney Diseases have identified glucagon receptor co-agonism as one of the most promising emerging strategies for reducing hepatic fat independent of caloric restriction [2], lending mechanistic plausibility to the retatrutide hypothesis even in the absence of dedicated trial data.

Practical Considerations for Clinicians Prescribing Off-Label

• Document everything. Chart the off-label discussion, the patient's acknowledgment of investigational status, the absence of approved alternatives that were appropriate, and the monitoring plan.
• Use a structured titration schedule. The phase 2 protocol started at 0.5 mg weekly and titrated to 2, 4, 8, or 12 mg over 24 weeks. Reproducing a similar slow titration may reduce GI adverse event burden.
• Set a clear 6-month decision point. If liver fat (MRI-PDFF) has not decreased by at least 20% relative from baseline and body weight has not decreased by at least 5%, the risk-benefit calculation should be revisited. Continuing a poorly effective off-label drug in a patient with progressive liver disease delays access to potentially more effective approved therapy.
• Coordinate with hepatology. MASH with F2 fibrosis or greater warrants co-management with a hepatologist regardless of which pharmacotherapy is used.
• Prepare the patient for access challenges. Retatrutide is not commercially available as of July 2025. Access typically requires either enrollment in a clinical trial, compassionate use, or compounding pharmacy sourcing, each carrying distinct regulatory and quality implications.

Patients with MASH and concurrent obesity who meet the criteria described above and who have documented failure of at least 6 months of lifestyle modification and resmetirom (if eligible) represent the narrowest, most defensible group for off-label retatrutide consideration. Begin the monitoring workup at least 2 weeks before the first dose.